bioAffinity Technologies — Third Quarter 2026 Earnings Summary

bioAffinity Technologies reported third-quarter 2026 results showing a 100% increase in CyPath Lung test unit sales compared to the first nine months of 2025, while testing revenue for the nine-month period rose 79% to approximately $1.1 million. The company expanded its commercial reach through a new distribution agreement with AvMEDICAL and advanced its clinical trial program with 11 active sites, including nine VA and military medical centers. Financially, the company recorded a net loss of approximately $5.3 million for the quarter, driven by increased operating expenses related to commercialization and clinical development, though it raised $8.0 million in gross proceeds through private and direct offerings in August and October 2026.